Published on : Apr 10, 2017
Albany, New York, April 10, 2017: The 72 pages report conducts a detailed analysis of the numerous proton therapy centers across the US. The nature of reimbursement policies for manufacturers, patients, stakeholders, and institutions has also been studied. The challenges and drivers of the proton therapy market in the US are also included, apart from an insightful section on vendor analysis.
Also known as proton beam therapy, proton therapy is a radiation therapy that involves the use of protons in the treatment of cancer. The proton, a positively charged particle, is capable of destroying cancer cells at high energy. A machine called cyclotron or synchrotron is used to speed up the protons, boosting their energy level. The resultant high energy protons penetrate deeper into the body to combat cancer cells by depositing radiation dose in the tumor. Proton therapy can be used in combination with other treatments such as chemotherapy, standard radiation therapy, and immunotherapy.
The rising concerns about the side effects of radiation therapies for treating cancer have been discouraging several patients from opting for these treatments. This will in turn tip scales in favor of the global proton therapy market in the coming years. This is because of the fact that in proton therapy, radiation hardly affects the healthy tissues in the body. Also, the quickness of the treatment ensures that the patient does not have to stay overnight in a hospital. All this has stoked the growth of the proton therapy market in the US.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=1037719
High awareness about health, technological advancements, favorable government policies, and heavy investments in healthcare have aided the expansion of the proton therapy market in the US. Proton therapy has treated nearly 80,000 cancer patients suffering from different forms of cancers such as brain tumors and prostate cancer.
The rising incidence of cancer worldwide is a prominent growth driver of the market. The American Cancer Society estimates that 1,688,780 new cases of cancer could be reported in the country by the end of 2017, leading to nearly 600,920 deaths. Furthermore, the incorporation of proton beam therapy in radiotherapy enhances precision of delivery. Therefore, the market will gain significant impetus, reaching a decent amount of revenue by the end of the forecast period.
By component, nozzle, image viewers, beam transport system, linacs, cyclotrons, beam scanning, super conducting cyclotrons, patient positioning system, and fast cycling synchrotron are some of the key segments in the market for proton therapy market in the US.
Some of the major companies operating in the US proton therapy market are Elekta, IBA Proton Therapy, and Varian Medical Systems.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org